Boundless Bio (BOLD) vs Talphera (TLPH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Boundless Bio (BOLD) has outperformed Talphera (TLPH) over the past year, gaining 98.5% versus a loss of 18.2%. Boundless Bio is the larger company by market cap ($57.6 million vs $56.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLD | TLPH |
|---|---|---|
| Share price | $2.53 | $1.08 |
| Market cap | $57.55M | $56.06M |
| 1-day change | -1.94% | 0.00% |
| YTD return | +115.00% | -5.26% |
| 1-year return | +98.46% | -18.18% |
| 5-year return | — | -94.71% |
| EPS (TTM) | $-2.85 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.16 | $1.57 |
| 52-week low | $0.961 | $0.69 |
| Distance from 52-week high | -20.04% | -31.21% |
| Analyst consensus | none | none |
| Avg. price target upside | +58.10% | +189.81% |
| Average volume | 182.04K | 238.38K |
| Shares outstanding | 22.75M | 51.91M |
| Employees | 28 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BOLD has outperformed TLPH by 116.6 percentage points over the past year.
About Boundless Bio
BOLD stock →Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Talphera
TLPH stock →Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
BOLD vs TLPH FAQ
Which is bigger, Boundless Bio or Talphera?
Boundless Bio (BOLD) is larger, with a market capitalization of $57.55M compared with $56.06M for Talphera (TLPH).
Which stock has performed better over the past year, BOLD or TLPH?
BOLD returned +98.46% over the past 12 months, compared with -18.18% for TLPH (price return, excluding dividends). Past performance does not predict future results.
Are Boundless Bio and Talphera in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.